Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Clin Cancer Res. 2011 Jan 15;17(2):203-5. doi: 10.1158/1078-0432.CCR-10-2825. Epub 2010 Nov 24.

    Blinded by the light: molecular imaging in pancreatic adenocarcinoma.

    Source

    Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA. mtempero@medicine.ucsf.edu

    Abstract

    The early detection and optimal perisurgical management of pancreatic adenocarcinoma are paramount goals in our quest to increase cure rates in this lethal malignancy. Molecular imaging techniques may be the conduit through which new genomic and proteomic discoveries about this disease are brought to the clinic.

    ©2010 AACR.

    Comment on

    • Plectin-1 as a novel biomarker for pancreatic cancer. [Clin Cancer Res. 2011]
    PMID:
    21106729
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk